PwPepwise

MOTS-c

Energy & Cells

Mitochondrial-encoded peptide (16-mer)

MOTS-c is a small peptide encoded not by the nuclear genome but by mitochondrial DNA.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
Endothelial/heart-related (ex vivo)2 µg/mL—IntraperitonealInjected into the abdominal cavity (research use).—

Approximate values pulled from the research — double-check before dosing.

§01Summary

MOTS-c is a small peptide encoded not by the nuclear genome but by mitochondrial DNA — the genetic material housed inside the energy-producing organelles of every cell. This makes it part of a newly recognized family of mitochondrial-derived peptides (MDPs) that act as signaling molecules, communicating the metabolic state of mitochondria to the rest of the body. Circulating MOTS-c levels appear to reflect metabolic health: levels have been reported to be lower in individuals with obesity10, insulin resistance10, coronary endothelial dysfunction8, Type 1 diabetes12, and chronic fatigue conditions15, while exercise may raise them in certain populations2,3,7.

In preclinical models, MOTS-c has been reported to improve insulin sensitivity, support healthy body composition, enhance physical performance across age groups, and protect against autoimmune destruction of insulin-producing cells6,7,12. It appears to act through the energy-sensing AMPK pathway and may also regulate gene expression directly inside the cell nucleus in response to metabolic stress5. The first Phase 2a clinical trial evaluating MOTS-c as a therapeutic agent in adults with prediabetes and overweight or obesity is currently underway1, representing an important milestone for this class of mitochondrial-derived therapeutics. Human efficacy data are actively emerging.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1), making it one of a small family of mitochondrial-derived peptides (MDPs) translated from the mitochondrial genome rather than nuclear DNA. Its primary amino acid sequence (CRQGSGLMDKGYALYR) contains a functional domain that enables cellular uptake and intracellular signaling, and naturally occurring variants such as the East Asian-specific K14Q substitution (m.1382A>C, rs111033358) demonstrate measurably reduced bioactivity6,18.

At the molecular level, MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. This activation promotes glucose uptake, fatty acid oxidation, and metabolic flexibility, particularly under conditions of nutrient stress5,6,16. A paradigm-shifting mechanistic discovery established that MOTS-c translocates to the cell nucleus in an AMPK-dependent manner under metabolic stress — including glucose restriction — where it directly regulates nuclear gene expression programs, particularly those governed by antioxidant response elements (ARE) and the NRF2/NFE2L2 transcription factor5. This retrograde mitochondrial-to-nuclear signaling axis represents a direct form of mitonuclear communication previously thought to be indirect.

In skeletal muscle and adipose tissue, MOTS-c modulates metabolic gene expression, myofiber composition (favoring slow-oxidative over fast-glycolytic phenotypes when active)18, and proteostasis7. In the hypothalamus, MOTS-c is expressed in POMC neurons and, when centrally administered, recapitulates exercise-induced adipose thermogenesis via the mitochondrial unfolded protein response (UPRmt), suggesting a brain-to-fat hormetic signaling axis9. An adiponectin-MOTS-c bidirectional feedback loop has been characterized in skeletal muscle, operating through the APPL1-SIRT1-PGC-1α pathway, where each molecule induces the other's expression13.

In endothelial systems, MOTS-c protects microvascular barrier integrity via inhibition of JNK-mediated phosphorylation of profilin at serine 173, thereby preserving F-actin polymerization and lamellipodia structure19. In pulmonary endothelial cells, protection against ischemia-reperfusion injury involves AMPK-HIF-1α-PFKFB3-driven glycolytic reprogramming and suppression of ferroptosis20. In the spinal cord, intrathecally administered MOTS-c activates AMPKα1/2, reduces proinflammatory cytokines, and attenuates neuronal oxidative damage through an opioid-receptor-independent mechanism16. These converging lines of mechanistic evidence position MOTS-c as a pleiotropic stress-responsive peptide whose cellular actions span metabolic reprogramming, nuclear gene regulation, immune modulation, cytoskeletal dynamics, and cell death pathway suppression.

§04Evidence & efficacy

Evidence base
261Studies
92Human
51Animal

MOTS-c's most extensively studied potential indication is metabolic disease, particularly insulin resistance and glucose homeostasis. In high-fat diet male mice, wild-type MOTS-c administration reduced body weight and improved glucose tolerance, while a naturally occurring variant (K14Q) with diminished bioactivity failed to replicate these effects, providing mechanistic validation of function6. Exercise-induced elevations in endogenous MOTS-c in Non-Hispanic White breast cancer survivors correlated with reductions in fat mass, HOMA-IR, and CRP, and increases in lean mass2. The first Phase 2a RCT targeting insulin sensitivity improvement in prediabetic adults is underway, with results pending1.

MOTS-c may support physical performance and healthy aging: exogenous administration enhanced physical capacity in young, middle-aged, and old mice, and late-life initiated intermittent treatment improved healthspan metrics7. Exercise induces endogenous MOTS-c expression in both human skeletal muscle and circulation7, and acute endurance exercise produced a trend toward elevated circulating MOTS-c in humans, though this did not reach statistical significance3.

Preliminary evidence from animal and mechanistic studies suggests MOTS-c may protect pancreatic beta cells from autoimmune destruction12, attenuate neuropathic pain via AMPK-dependent spinal cord mechanisms16, support coronary endothelial function8, and protect against cardiopulmonary bypass-associated lung injury via AMPK-HIF-1α-PFKFB3-mediated glycolytic reprogramming20. A novel role in endothelial barrier preservation during septic myocardial injury has also been described through the MOTS-c/JNK/profilin axis19.

In the context of muscle biology, the K14Q polymorphism — which reduces MOTS-c bioactivity — is associated with a shift toward fast-twitch muscle fiber composition and enrichment in sprint/power athletes, introducing a nuanced, context-dependent picture of MOTS-c's functional role18.

§05Safety

Formal human safety data for exogenous MOTS-c administration are not yet available in the published literature. The Phase 2a clinical trial (NCT07505745) includes safety as a formal endpoint with monitoring through Week 16, but no adverse event data have been reported1.

Preclinical safety signals have been generally favorable. In a neuropathic pain mouse model, intrathecal MOTS-c showed limited tolerance development, minimal gastrointestinal transit inhibition, and no significant locomotor impairment, comparing favorably to morphine on these parameters16. No adverse events or toxicity concerns were reported in metabolic studies using intraperitoneal MOTS-c in high-fat diet mice6,13. No explicit safety concerns were raised in studies using central (intracerebroventricular) administration in rodents9.

One mechanistically relevant observation from animal models is that severe mitoribosomal stress in hypothalamic POMC neurons — which induces excessive endogenous MOTS-c upregulation — was associated with obesity, suggesting that the degree and context of MOTS-c signaling activation may be important9. This is a finding from a genetic stress model rather than from exogenous peptide administration, and its relevance to therapeutic dosing is an area of active investigation.

Observational human studies report that circulating MOTS-c is elevated in individuals with metabolic syndrome, android fat accumulation, and liver fat — interpreted as a potential compensatory stress response rather than a harmful signal17. The clinical implications of this endogenous elevation pattern are being characterized through ongoing research.

§06History

MOTS-c was first described in 2015 by Lee, Cohen, and colleagues at the University of Southern California, who identified it as a peptide encoded within the mitochondrial 12S rRNA gene — a finding that challenged the long-standing assumption that mitochondrial DNA encodes only components of the respiratory chain and translational machinery. Initial studies demonstrated that MOTS-c regulated insulin sensitivity and metabolic homeostasis in mice and that circulating levels declined with age, positioning it as a potential mediator of age-associated metabolic decline.

A landmark 2018 study published in Cell Metabolism established that MOTS-c translocates to the nucleus under metabolic stress in an AMPK-dependent manner, directly regulating nuclear gene expression programs — the first demonstration of retrograde genetic regulation by a mitochondrially-encoded peptide5. This finding generated substantial scientific interest (294 citations) and redefined models of mitonuclear communication.

Subsequent years saw rapid expansion of the research landscape. A 2021 study confirmed MOTS-c as an exercise-induced regulator of muscle homeostasis and physical performance across the lifespan in both mice and humans7. The same year, a pro-diabetogenic mtDNA polymorphism (K14Q) was characterized across human cohorts and mouse models6, revealing pharmacogenomically relevant variation. MOTS-c's role in autoimmune diabetes12, neuropathic pain16, cardiovascular endothelial function8, and hypothalamic metabolic signaling9 were progressively defined through 2020–2024. The initiation of a Phase 2a RCT in prediabetes and obesity by Hudson Biotech1 marks the transition of MOTS-c from a basic science discovery into active clinical development.

§07References